원텍
Financials
Valuation Metrics
원텍's Market Cap is ₩3915B. At end of 2025 it was ₩6919B. Ranked #531 of 2,414 in KR market (top 22%), #206 of 1,633 on KOSDAQ (top 13%), #15 of 94 in Health Care Equipment & Services (top 16%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 391.50B KRW | KR#531/2,414 Sec#15/94 |
| Revenue | 167.35B KRW | KR#1,122/2,414 Sec#17/94 |
| Net Income | 39.99B KRW | KR#488/2,414 Sec#11/94 |
| Total Assets | 278.76B KRW | KR#1,078/2,414 Sec#25/94 |
| Net Assets | 173.02B KRW | KR#1,041/2,414 Sec#27/94 |
| Employees | 228 | KR#1,002/2,414 Sec#30/94 |
| Value | ||
| P/E | 9.79x | KR#835/2,414 Sec#27/94 |
| P/B | 2.26x | KR#2,025/2,414 Sec#71/94 |
| PEG | 33.13x | KR#834/2,414 Sec#33/94 |
| P/S | 2.34x | KR#1,917/2,414 Sec#59/94 |
| EV/EBITDA | 9.24x | KR#606/2,414 Sec#19/94 |
| FCF Yield | 12.76% | KR#536/2,414 Sec#10/94 |
| Profitability | ||
| ROE | 23.11% | KR#126/2,414 Sec#5/94 |
| ROA | 14.34% | KR#129/2,414 Sec#9/94 |
| Op. Margin | 25.19% | KR#93/2,414 Sec#6/94 |
| Revenue Growth | 18.77% | KR#584/2,414 Sec#31/94 |
| Earnings Growth | 0.30% | KR#829/2,414 Sec#33/94 |
| Financial Health | ||
| Debt Ratio | 61.12% | KR#1,109/2,414 Sec#63/94 |
| Total Debt | 31.24B KRW | KR#1,206/2,414 Sec#30/94 |
| FCF | 49.94B KRW | KR#298/2,414 Sec#4/94 |
| Cash | 33.08B KRW | KR#943/2,414 Sec#24/94 |
| Current Ratio | 6.44x | KR#190/2,414 Sec#18/94 |
| Net Debt/EBITDA | -0.04x | KR#598/2,414 Sec#23/94 |
| Dividend | ||
| Div. Yield | 1.14% | KR#1,105/2,414 Sec#35/94 |
| Div. Growth | 0.00% | KR—/2,414 Sec—/94 |
| Performance | ||
| 1Y Return | -50.56% | KR#2,013/2,414 Sec#71/94 |
| 1M Return | -12.30% | KR#1,738/2,414 Sec#72/94 |
| From 52W High | -58.16% | KR#1,635/2,414 Sec#53/94 |
| 1Y MDD | -57.14% | KR#1,308/2,414 Sec#45/94 |
| Trading | ||
| Volume | 559,569 shares | KR#233/2,414 Sec#6/94 |
| Trading Value | 2.44B KRW | KR#535/2,414 Sec#11/94 |
| Foreign Own. | 3.36% | KR#1,182/2,414 Sec#40/94 |
| Per Share | ||
| EPS | 448 KRW | KR#1,034/2,414 Sec#29/94 |
| BPS | 1,938 KRW | KR#2,089/2,414 Sec#70/94 |
Company Info
Established in 1999 as a specialized medical device company, Wontech is headquartered in Yuseong-gu, Daejeon Metropolitan City, having completed a merger with Daishin Balance No. 8 Special Purpose Acquisition Company in 2022. It primarily manufactures and sells skin aesthetics lasers and energy-based medical devices, including Oligio, Picocare, and Lavieen, actively exporting to Asia, Europe, the Middle East, and South America. The company diversifies its product lineup through RF and HIFU technology development and strengthens competitiveness by developing Monopolar RF Oligio.